Literature DB >> 19419892

Activation of glycolysis and apoptosis in glycogen storage disease type Ia.

Baodong Sun1, Songtao Li, Liu Yang, Tirupapuliyur Damodaran, Dev Desai, Anna Mae Diehl, Oscar Alzate, Dwight D Koeberl.   

Abstract

The deficiency of glucose-6-phosphatase (G6Pase) underlies glycogen storage disease type Ia (GSD-Ia, von Gierke disease; MIM 232200), an autosomal recessive disorder of metabolism associated with life-threatening hypoglycemia, growth retardation, renal failure, hepatic adenomas, and hepatocellular carcinoma. Liver involvement includes the massive accumulation of glycogen and lipids due to accumulated glucose-6-phosphate and glycolytic intermediates. Proteomic analysis revealed elevations in glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and other enzymes involved in glycolysis. GAPDH was markedly increased in murine G6Pase-deficient hepatocytes. The moonlighting role of GAPDH includes increasing apoptosis, which was demonstrated by increased TUNEL assay positivity and caspase 3 activation in the murine GSD-Ia liver. These analyses of hepatic involvement in GSD-Ia mice have implicated the induction of apoptosis in the pathobiology of GSD-Ia.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19419892     DOI: 10.1016/j.ymgme.2009.04.003

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  10 in total

1.  In Vivo Zinc Finger Nuclease-mediated Targeted Integration of a Glucose-6-phosphatase Transgene Promotes Survival in Mice With Glycogen Storage Disease Type IA.

Authors:  Dustin J Landau; Elizabeth Drake Brooks; Pablo Perez-Pinera; Hiruni Amarasekara; Adam Mefferd; Songtao Li; Andrew Bird; Charles A Gersbach; Dwight D Koeberl
Journal:  Mol Ther       Date:  2016-02-11       Impact factor: 11.454

2.  In search of proof-of-concept: gene therapy for glycogen storage disease type Ia.

Authors:  Dwight D Koeberl
Journal:  J Inherit Metab Dis       Date:  2012-02-07       Impact factor: 4.982

Review 3.  Glycogen storage disease type I and G6Pase-β deficiency: etiology and therapy.

Authors:  Janice Y Chou; Hyun Sik Jun; Brian C Mansfield
Journal:  Nat Rev Endocrinol       Date:  2010-10-26       Impact factor: 43.330

4.  Long-term efficacy following readministration of an adeno-associated virus vector in dogs with glycogen storage disease type Ia.

Authors:  Amanda Demaster; Xiaoyan Luo; Sarah Curtis; Kyha D Williams; Dustin J Landau; Elizabeth J Drake; Daniel M Kozink; Andrew Bird; Bayley Crane; Francis Sun; Carlos R Pinto; Talmage T Brown; Alex R Kemper; Dwight D Koeberl
Journal:  Hum Gene Ther       Date:  2012-03-08       Impact factor: 5.695

Review 5.  Preclinical Development of New Therapy for Glycogen Storage Diseases.

Authors:  Baodong Sun; Elizabeth D Brooks; Dwight D Koeberl
Journal:  Curr Gene Ther       Date:  2015       Impact factor: 4.391

6.  Fenofibrate rapidly decreases hepatic lipid and glycogen storage in neonatal mice with glycogen storage disease type Ia.

Authors:  Zollie A Yavarow; Hye-Ri Kang; Lauren R Waskowicz; Boon-Huat Bay; Sarah P Young; Paul M Yen; Dwight D Koeberl
Journal:  Hum Mol Genet       Date:  2020-01-15       Impact factor: 6.150

7.  Bezafibrate induces autophagy and improves hepatic lipid metabolism in glycogen storage disease type Ia.

Authors:  Lauren R Waskowicz; Jin Zhou; Dustin J Landau; Elizabeth D Brooks; Andrea Lim; Zollie A Yavarow; Tsubasa Kudo; Haoyue Zhang; Yajun Wu; Stuart Grant; Sarah P Young; Bay Boon Huat; Paul M Yen; Dwight D Koeberl
Journal:  Hum Mol Genet       Date:  2019-01-01       Impact factor: 6.150

8.  Long-term complications of glycogen storage disease type Ia in the canine model treated with gene replacement therapy.

Authors:  Elizabeth D Brooks; Dustin J Landau; Jeffrey I Everitt; Talmage T Brown; Kylie M Grady; Lauren Waskowicz; Cameron R Bass; John D'Angelo; Yohannes G Asfaw; Kyha Williams; Priya S Kishnani; Dwight D Koeberl
Journal:  J Inherit Metab Dis       Date:  2018-07-24       Impact factor: 4.982

9.  Hepatic mitochondrial dysfunction is a feature of Glycogen Storage Disease Type Ia (GSDIa).

Authors:  Benjamin L Farah; Rohit A Sinha; Yajun Wu; Brijesh K Singh; Andrea Lim; Masahiro Hirayama; Dustin J Landau; Boon Huat Bay; Dwight D Koeberl; Paul M Yen
Journal:  Sci Rep       Date:  2017-03-20       Impact factor: 4.379

10.  Bezafibrate Enhances AAV Vector-Mediated Genome Editing in Glycogen Storage Disease Type Ia.

Authors:  Hye-Ri Kang; Lauren Waskowicz; Andrea M Seifts; Dustin J Landau; Sarah P Young; Dwight D Koeberl
Journal:  Mol Ther Methods Clin Dev       Date:  2019-02-10       Impact factor: 6.698

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.